The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

This Nasdaq biotech in my Stocks and Shares ISA portfolio just got a shot in the arm. Here's why I'm almost past caring at this point. The post Up 14% yesterday, is it the end for this train wreck in ...

Durban-headquartered pharmaceutical major Aspen Pharmacare confirmed in a Sens announcement on Friday that it has reached a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical ...

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee ...